Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Infectious Diseases

    Dublin-Boston Scoring System Helps Predict Which COVID-19 Patients Will Develop Severe Infection

    By Global Biodefense StaffOctober 14, 2020
    Professor Gerry McElvaney (L), the study's senior author and a consultant in Beaumont Hospital, and Professor Ger Curley (R) stand in front of the RCSI Education and Research Centre in Beaumont Hospital, Dublin. Credit: Ray Lohan
    Share
    Facebook LinkedIn Reddit Email

    A new COVID-19 patient assessment system, called the Dublin-Boston score, is designed to enable clinicians to make more informed decisions when identifying patients who may benefit from therapies, such as steroids, and admission to intensive care units.

    The blood test works by measuring the levels of two molecules that send messages to the body’s immune system and control inflammation. One of these molecules, interleukin (IL)-6, is pro-inflammatory, and a different one, called IL-10, is anti-inflammatory. The levels of both are altered in severe Covid-19 patients.

    Based on the changes in the ratio of these two molecules over time, the researchers developed a point system where each 1-point increase was associated with a 5.6 times increased odds for a more severe outcome.

    The Dublin-Boston score uses the ratio of IL-6 to IL-10 because it significantly outperformed measuring the change in IL-6 alone.

    Findings on use of the scoring system, led by researchers at RCSI University of Medicine and Health Sciences, were published in The Lancet’s translational research journal EBioMedicine.

    Until this study, no Covid-19-specific prognostic scores were available to guide clinical decision-making. The Dublin-Boston score can now accurately predict how severe the infection will be on day seven after measuring the patient’s blood for the first four days.

    “The Dublin-Boston score is easily calculated and can be applied to all hospitalised Covid-19 patients,” said RCSI Professor of Medicine Gerry McElvaney, the study’s senior author and a consultant in Beaumont Hospital.

    “More informed prognosis could help determine when to escalate or de-escalate care, a key component of the efficient allocation of resources during the current pandemic. The score may also have a role in evaluating whether new therapies designed to decrease inflammation in Covid-19 actually provide benefit.”

    Despite high levels in blood, using only IL-6 measurements as a Covid-19 prognostic tool is hindered by several factors. IL-6 levels within the same patient vary over the course of any given day, and the magnitude of the IL-6 response to infection varies between different patients.

    The Dublin-Boston score was developed by researchers from RCSI, Harvard University, Beaumont Hospital in Dublin and the Brigham and Women’s Hospital in Boston.

    A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. EBioMedicine, 8 October 2020.

    COVID-19 Editor Pick Medicine-Health SARS-CoV-2
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleW. Virginia CBRN Response Enterprise Assists with COVID-19 Testing Innovation Roll Out
    Next Article DoD Expands U.S. Domestic Diagnostics Capacity with $481M Cue Health Deal

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    Provide Feedback on Federal DURC Biosafety Oversight of Potential Pandemic Pathogens

    September 24, 2023

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.